Pages that link to "Q30886032"

The following pages link to Twenty-seven years of phase III trials for patients with extensive disease small-cell lung cancer: disappointing results (Q30886032):

Displaying 45 items.

• Chemotherapy versus best supportive care for extensive small cell lung cancer (Q24202339) (← links)
• What future opportunities may immuno-oncology provide for improving the treatment of patients with lung cancer? (Q27012886) (← links)
• Role of survival post-progression in phase III trials of systemic chemotherapy in advanced non-small-cell lung cancer: a systematic review (Q27025724) (← links)
• Valproic acid improves second-line regimen of small cell lung carcinoma in preclinical models (Q28596812) (← links)
• Small cell lung cancer: where do we go from here? (Q33872327) (← links)
• Upfront stereotactic radiosurgery in patients with brain metastases from small cell lung cancer: retrospective analysis of 41 patients (Q33904109) (← links)
• Expression of p300 and CBP is associated with poor prognosis in small cell lung cancer (Q34039929) (← links)
• Treatment-related death in patients with small-cell lung cancer in phase III trials over the last two decades (Q34374754) (← links)
• Modified one-day etoposide and cisplatin combination for previously untreated extensive-disease small-cell lung cancer: A retrospective evaluation of 36 cases (Q35802946) (← links)
• Rapamycin rescues ABT-737 efficacy in small cell lung cancer (Q35878431) (← links)
• Prognostic factors affecting the risk of thoracic progression in extensive-stage small cell lung cancer (Q38639757) (← links)
• DNA methylation in small cell lung cancer defines distinct disease subtypes and correlates with high expression of EZH2. (Q36042596) (← links)
• Vorinostat enhances the cisplatin-mediated anticancer effects in small cell lung cancer cells. (Q36184617) (← links)
• Clinical trials in advanced stage lung cancer: a survey of patients' opinion about their treatment (Q36293866) (← links)
• Poly(β-amino ester) nanoparticle delivery of TP53 has activity against small cell lung cancer in vitro and in vivo (Q36759358) (← links)
• Perspective: Opportunities in recalcitrant, rare and neglected tumors (Q37197528) (← links)
• Outcome and Biomarker Analysis from a Multicenter Phase 2 Study of Ipilimumab in Combination with Carboplatin and Etoposide as First-Line Therapy for Extensive-Stage SCLC. (Q37338005) (← links)
• The Janus kinases inhibitor AZD1480 attenuates growth of small cell lung cancers in vitro and in vivo (Q37412314) (← links)
• Selective tropism of Seneca Valley virus for variant subtype small cell lung cancer. (Q37463325) (← links)
• Novel strategies for the treatment of small-cell lung carcinoma (Q37892341) (← links)
• Cisplatin plus etoposide versus other platin‐based regimens for patients with extensive small‐cell lung cancer: a systematic review and meta‐analysis of randomised, controlled trials (Q38005201) (← links)
• Cell-free microRNAs as diagnostic, prognostic, and predictive biomarkers for lung cancer. (Q38081132) (← links)
• Targeting small cell lung cancer harboring PIK3CA mutation with a selective oral PI3K inhibitor PF-4989216. (Q39062455) (← links)
• Small cell lung cancer tumour cells induce regulatory T lymphocytes, and patient survival correlates negatively with FOXP3 cells in tumour infiltrate (Q39359136) (← links)
• Intrathoracic extensive-stage small cell lung cancer: assessment of the benefit of thoracic and brain radiotherapy using the SEER database (Q39630288) (← links)
• Anticancer activity and mode of action of titanocene C. (Q39738480) (← links)
• Anthrax toxin receptor 1 is the cellular receptor for Seneca Valley virus. (Q40145604) (← links)
• Noninvasive Interrogation of DLL3 Expression in Metastatic Small Cell Lung Cancer (Q40208474) (← links)
• The role of hyperparasitism in microbial pathogen ecology and evolution (Q40966222) (← links)
• Effective growth-suppressive activity of maternal embryonic leucine-zipper kinase (MELK) inhibitor against small cell lung cancer (Q41900139) (← links)
• TOPK (T-LAK cell-originated protein kinase) inhibitor exhibits growth suppressive effect on small cell lung cancer (Q42292977) (← links)
• Small Cell Lung Cancer Patient with Profound Hyponatremia and Acute Neurological Symptoms: An Effective Treatment with Fludrocortisone (Q42380825) (← links)
• Outcomes in recurrent small-cell lung cancer after one to four chemotherapy lines: A retrospective study of 300 patients (Q43874461) (← links)
• Characterization of fibroblast growth factor receptor 1 in small-cell lung cancer. (Q47133414) (← links)
• Prognostic factors and survival of patients with small cell lung cancer in a northeastern Chinese population (Q50050610) (← links)
• Assessment of neuronal autoantibodies in patients with small cell lung cancer treated with chemotherapy with or without ipilimumab. (Q50426020) (← links)
• [First-line chemotherapy and its survival analysis of 394 patients with extensive-stage small cell lung cancer in a single institute]. (Q55428299) (← links)
• Advances about treatment of small cell lung cancer (Q55464332) (← links)
• Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial (Q56897633) (← links)
• Checkpoint Inhibition: Will Combination with Radiotherapy and Nanoparticle-Mediated Delivery Improve Efficacy? (Q58576243) (← links)
• Managing Patients With Relapsed Small-Cell Lung Cancer. (Q64910923) (← links)
• Small-cell lung cancer (Q84084759) (← links)
• MET Inhibitors in Small Cell Lung Cancer: From the Bench to the Bedside (Q90227747) (← links)
• Serum cytokine levels as predictive biomarkers of benefit from ipilimumab in small cell lung cancer (Q91868667) (← links)
• RRx-001 followed by platinum plus etoposide in patients with previously treated small-cell lung cancer (Q92969721) (← links)